IL-17, IL-23 and IL-12/23 biologics on AARP Medicare Rx Preferred from UHC (S5921-410)
Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Nevada
- Premium
- $139.10/month
- Deductible
- $130.00, doesn't apply to tier 1 and 2
3 of 9 IL-17 and IL-23 biologics are covered on this plan. All 3 require prior authorization.
6 aren't on the formulary, including Stelara and ustekinumab biosimilars.
- from $3,085.29Tier 5
- from $4,805.08Tier 5
- from $12,794.59Tier 5
Not on the formulary
Stelara, ustekinumab biosimilars, Wezlana, Selarsdi, Taltz, Bimzelx
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $130.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.